Biotech Insider AlertTouting a $4 Stock with $28M in sales that has a new drug in Phase trials for Uveitis – eye disease. It has been granted ”Orphan Status” by FDA and Phase trial data is due out very soon. ?What is the stock and is this real? He wants $1950 for one year subscription to the newsletter.
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
Am interested also in learning about the company being promoted by Biotech Insider Alert because of a potential Uveitis cure.
I don’t know anything about the company but I do believe it is http://www.xoma.com
It is indeed XOMA and is old rehash previously covered by SGS
It seems a biotech drug from blue blood may change the science for cancer cure. No one knows what the drug name yet. If you keep an eye of publications they may cite this drug any time in future.
Not anytime soon. We covered that one here: http://www.stockgumshoe.com/reviews/alternative-energy-speculator/blue-blood-which-tiny-biotech-owns-only-source-of-rare-cancer-curing-chemical/